12:00 AM
 | 
Oct 26, 2015
 |  BioCentury  |  Finance

Neo is the time

Why VCs flocked to Andrew Allen's cancer newco Gritstone

With a resume that includes Pharmion Corp. and Clovis Oncology Inc. (NASDAQ:CLVS), Andrew Allen did not suffer from a lack of VC interest for his newest cancer venture. His Gritstone Oncology Inc. launched last week and raised $102 million in the third-largest biotech series A round this year.

Versant Ventures and The Column Group led the round. Other investors included Clarus Ventures, Frazier Healthcare, Redmile Group, Casdin Capital and Transformational Healthcare Opportunity.

Gritstone is developing personalized,...

Read the full 388 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >